Moderna (NASDAQ:MRNA) Price Target Lowered to $99.00 at The Goldman Sachs Group

Moderna (NASDAQ:MRNA) had its price objective reduced by equities research analysts at The Goldman Sachs Group from $112.00 to $99.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price indicates a potential upside of 143.12% from the stock’s current price.

A number of other research firms also recently issued reports on MRNA. Berenberg Bank increased their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Evercore ISI decreased their price target on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a research report on Monday. Jefferies Financial Group cut their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. Finally, Morgan Stanley reduced their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $67.26.

Moderna Stock Performance

Shares of MRNA stock opened at $40.72 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The firm has a market capitalization of $15.67 billion, a price-to-earnings ratio of -7.00 and a beta of 1.60. Moderna has a one year low of $31.94 and a one year high of $170.47. The company has a 50 day moving average price of $40.87 and a 200 day moving average price of $62.03.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the prior year, the firm posted ($1.39) EPS. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. Sell-side analysts anticipate that Moderna will post -9.27 EPS for the current year.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 2,664 shares of company stock valued at $115,210 over the last three months. 15.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Moderna

Several large investors have recently added to or reduced their stakes in MRNA. State Street Corp lifted its holdings in Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the period. Two Sigma Advisers LP bought a new stake in shares of Moderna in the 3rd quarter worth approximately $23,825,000. International Assets Investment Management LLC grew its stake in Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after buying an additional 316,552 shares during the last quarter. Finally, Douglas Lane & Associates LLC increased its position in Moderna by 62.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after buying an additional 298,715 shares during the period. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.